Supporting a new era of diagnostics with Unilabs

Trusted diagnostics. Informed decisions. Better care.

Healthcare across Europe is evolving. Demand is increasing, conditions are becoming more complex, and expectations for faster, more accurate and more personalised care continue to rise. Across countries, healthcare professionals, systems, partners and patients are all navigating growing pressure to make the well‑informed decisions, at the right time.

Across Europe, Unilabs brings together diagnostic expertise, technologies and capabilities across multiple modalities to support informed healthcare decisions.

About Unilabs Our services

About Unilabs

Powering health by supporting informed decisions every day

For over three decades, since our founding in Switzerland, Unilabs has been dedicated to supporting healthcare through diagnostic insight, scientific expertise and innovation.

Today, Unilabs is one of the few full‑spectrum diagnostics providers supporting the needs of healthcare professionals across four diagnostic modalities combining Clinical Laboratory Testing, Radiology, Pathology and Genetics.

Our scale allows us to combine local expertise with the strength of a wider network. Working alongside healthcare providers and partners across countries, we help deliver high‑quality diagnostics and meaningful insight where they are needed most.

Our capabilities

Clinical Laboratory Testing

Where insights begin

Laboratory diagnostics provide the foundation for clinical decision‑making. At Unilabs, we deliver accurate, timely and clinically meaningful information and insights that support diagnosis, treatment and monitoring across a wide range of conditions. Supported by one of Europe’s strongest medical networks, our team of more than 500 laboratory doctors, including microbiologists, haematologists, chemists and immunologists, contributes deep subspecialty expertise to support informed clinical decision‑making.

Find out more

Group CEO

Badhri Srinivasan

“Behind every test is a person. And behind every person is a story — of uncertainty, courage, and hope. Whether it’s a scan, a blood test, or a biopsy, millions of people come to us seeking clarity, dignity, and answers. This is both a privilege and a profound responsibility that we carry with pride.

Meet our team

Science

World Ovarian Cancer Day: improving early detection through advanced diagnostics

Each year on 8 May, World Ovarian Cancer Day brings global attention to one of the most challenging gynaecological cancers. Ovarian cancer is not a single disease but a group of distinct tumour types affecting the ovaries, fallopian tubes, or peritoneum. According to the World Health Organization, ovarian cancer encompasses more than 30 distinct histological subtypes, each with its own prevalence, molecular characteristics, and clinical outcomes. The most common types include high-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, and mucinous carcinoma, but rarer forms are also recognised, each requiring tailored diagnostic and therapeutic approaches. Despite medical advances, ovarian cancer remains the deadliest cancer of the female reproductive system. According to the American Cancer Society, over 70% of cases are diagnosed at an advanced stage because early symptoms—like bloating, abdominal pain, or changes in bowel habits—are vague and often missed. There is currently no effective screening for average-risk women. As Dr Eugenia Colón notes, most patients are diagnosed late, making treatment more challenging and survival rates lower. Early detection and symptom awareness are therefore critical to improving outcomes. (American Cancer Society, 2026) The role of pathology in diagnosis Pathology is essential for diagnosing ovarian cancer and guiding treatment. Ovarian cancer is highly heterogeneous, with tumour subtype, patterns, and molecular features directly affecting prognosis and therapy (Smolarz et al., 2026). At Unilabs, pathologists must provide clear, actionable diagnoses by closely examining tissue samples, assessing cell appearance, growth patterns, and key markers. The integration of molecular and biomarker analysis has improved accuracy and enabled more personalised treatment (Miccolis et al., 2026). New technologies, like digital pathology and artificial intelligence, also help increase precision and consistency in ovarian cancer diagnosis (Gülmez et al., 2026). Accurate pathology remains the foundation for optimal patient care. How advanced diagnostics and molecular testing are transforming diagnosis In recent years, ovarian cancer diagnostics have undergone a profound transformation, driven by the rapid integration of molecular testing into routine pathology practice. What was once primarily based on morphology has evolved into a more comprehensive and precise discipline, where genetic and biomarker profiling plays a crucial role. As Dr Colón describes, “The advent of molecular testing has introduced a new era of personalised medicine, where treatment can be tailored to the specific molecular profile of each tumour, maximising efficacy and minimising side effects for patients.” This shift is strongly supported by recent PubMed-indexed studies demonstrating that molecular profiling enables the identification of actionable mutations and biomarkers, allowing clinicians to individualise therapy and improve clinical outcomes (Zhang et al., 2024; Matias-Guiu et al., 2023). At the same time, this evolution places new demands on the role of the pathologist. Integrating molecular data with traditional histopathological assessment is not automatic—it requires continuous learning, critical interpretation, and close clinicopathological correlation. As Dr Colón emphasises, “As pathologists, we must continuously update our knowledge to effectively correlate morphological findings with molecular analyses. This synergy between traditional pathology and modern molecular techniques is paramount in guiding treatment decisions and improving patient outcomes.” Recent literature reinforces this perspective, highlighting that the combination of morphology, immunohistochemistry, and molecular diagnostics leads to personalised treatment strategies in ovarian cancer. The importance of continued progress in research Dr Colón says research has reshaped our understanding of ovarian cancer origins, demonstrating that many high-grade serous carcinomas arise from the distal fallopian tube, particularly from precursor lesions, such as serous tubal intraepithelial carcinoma (STIC) (Kurman & Shih, 2016). She highlights, “Groundbreaking discoveries, including work on pre-malignant lesions in the fallopian tubes, are opening new avenues for prevention and early intervention.” These insights have already influenced preventive strategies, including risk-reducing salpingectomy. For now, Dr Colón says early detection remains the most critical factor in improving survival rates. “That’s why, at Unilabs, we remain committed to advancing diagnostic excellence to support earlier detection, more precise diagnosis, and better outcomes for patients at every stage of care.”

Jun 30, 2026

Medical Research

Kamil Doležel on driving transformation in diagnostics across Central and Eastern Europe

From building high-performing teams across diverse markets to shaping systems that support superior decision-making, earlier interventions, and stronger healthcare outcomes, Kamil Doležel, General Manager Unilabs’ Central and Eastern Europe (CEE), shares his perspective on what it takes to be a leader in diagnostics. What attracts you to Unilabs? I joined Unilabs in 2017 following its acquisition of AeskuLabs, where I was CEO. Today, as General Manager, Unilabs CEE, I am responsible for the overall direction, performance, and development of our diagnostic services in the market. What drives me most is the tangible impact of our work, particularly the growing opportunity for Unilabs in the space of preventative healthcare. I believe diagnostics has the potential to shift healthcare from reacting to disease to proactively managing health. How do you describe the purpose of your role today? My role is to ensure that Unilabs CEE functions as a cohesive, reliable, and sustainable system, both internally and externally. This allows us to build long-term value for our customers, patients, and the healthcare eco-system, through timely, reliable, and high‑quality diagnostics. For this to happen, we must connect medical expertise, technology, and operations. Leadership in this context is not about isolated decisions, but about maintaining a system that works—and continuously improving it. I am surrounded by very strong leaders and colleagues who are helping me to run the strategy across the company. What is your leadership philosophy? I follow a simple principle: the journey is an aim. This doesn’t mean we shouldn’t have ambition or clear goals. It means that real value is created in how we work, how we decide, and how we move forward. Leadership, therefore, is not about one-off results, but about creating long-term direction, maintaining momentum, and continuously seeking better ways of doing things. At the same time, I strongly believe that success is built on people. A good leader must be able to listen, understand their environment, and bring out the best in their team members. This leadership philosophy extends to how we show up in the wider healthcare system too. To have a strong voice, we must be able to partner successfully with health authorities and create the future laboratory diagnostic environment alongside them. I believe Unilabs is evolving to become a critical link in a connected healthcare system — the organisations that will define the next decade of healthcare are those that take insights and turn them into meaningful, timely actions. Which experiences, professional or personal, have most shaped this philosophy? Early on, I learned that strategy alone doesn't deliver results, but people do. People perform at their best not when they are told what to do, but rather when they deeply understand what their role is. That's why I've always invested heavily in making sure every person in my team understands and owns a shared set of competencies: listening, respect, communication, delegation, teamwork, and delivering on commitments. These aren't values on a wall, but they're behaviours I model myself, and hold my team accountable to every day. Having had the pleasure of leading across very different cultures, Czech and Slovak, I have discovered a shared competency framework becomes an enormous asset in a cross-cultural environment. When everyone understands that we communicate openly, delegate with trust, respect each other's expertise and time, and act as one team, we suddenly have a common language that cuts through cultural noise. Where do you believe the greatest untapped opportunity lies today for healthcare organisations like Unilabs? Prevention, but not in the traditional sense of screenings and check-ups. Diagnostics is no longer simply about confirming a disease, it’s about supporting decision-making, prevention, and personalised care. We already have remarkable capabilities. With advancements in the industry, it‘s becoming possible to detect diseases, such as Alzheimer's, earlier than before. Genetic testing can identify cancer predispositions before a single symptom appears. Pathology and advanced diagnostics are saving lives that would have been lost a decade ago. What do you believe sets Unilabs apart in the diagnostics industry? There are three things I believe set us apart in the diagnostics industry: Firstly, our quality and scientific credibility. Our laboratories are fully accredited, operating to the highest international standards. Beyond accreditation, we have something more valuable: people. In our ranks, we have specialists who are internationally recognised; experts who contribute to shaping diagnostic standards across Europe, and sometimes the world. Secondly, we are part of a network that gives us early visibility into where diagnostics is heading, whether that is advances in genetic testing, new biomarkers for neurodegenerative diseases like Alzheimer's, or AI-assisted pathology. We translate that knowledge into real clinical practice across CEE. Thirdly, we are genuinely accessible. Not just geographically—with a presence across regions that many providers simply do not reach—but accessible in a human sense too. A physician who has a question about a complex result can pick up the phone and speak directly with one of our specialists. They can walk through the findings together, discuss the clinical implications, and make better decisions for their patient. What excites you most about the future of Unilabs? We are investing in the next generation of diagnostic talent. We open our doors to students, welcome them for internships, and give them a chance to see first-hand what modern laboratory diagnostics looks like. Many of them arrive expecting a traditional lab environment and leave understanding that this is one of the most dynamic, intellectually demanding fields in healthcare today. That brings me to what I find particularly exciting right now: AI. Not AI as a buzzword, but AI where it genuinely makes sense in laboratory diagnostics, in image analysis, in pattern recognition across large datasets, in supporting pathologists to work with greater speed and precision. We are embracing these tools thoughtfully, where they add real clinical value, and making sure our people are equipped to work alongside them, not be replaced by them. When I consider the future of Unilabs, I see an organisation where world-class expertise meets continuous learning, where young talent is nurtured from the very beginning of their career, and where technology amplifies human judgement, rather than substituting it.

Jun 2, 2026

Looking to partner with Unilabs? Talk to our team about diagnostic capacity, pharma solutions, Unilabs Academy, TMC or local services

Health starts with you

Title display 35 characters lore!

Title display 35 characters lorem ipsum dolor sit amet, consectetur adipiscing

Test